{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-021367","form_type":"8-K","ticker":"CCCC","cik":"0001662579","company_name":"C4 Therapeutics, Inc.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.482120+00:00","generated_at":"2026-06-02T10:44:10.440346+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"C4 Therapeutics Q1 net loss narrows to $28.4M; cash $299M into 2027; Biogen milestone $8M, Merck deal up to $740M","bullets":["Revenue $3.0M (down from $3.8M YoY); net loss per share $0.41 vs $0.71.","Cash $299.2M as of Mar 31; expected runway into 2027.","Earned $8M from Biogen; Merck KGaA collaboration with $16M upfront and up to $740M milestones.","Phase 1 trials for cemsidomide (MM/NHL) and CFT1946 (solid tumors) progressing; data expected 2H 2024.","Appointed Dan Powers as SVP clinical development."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-021367","json":"https://secwatch.observer/filing/0001628280-24-021367.json","markdown":"https://secwatch.observer/filing/0001628280-24-021367.md","text":"https://secwatch.observer/filing/0001628280-24-021367.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662579/000162828024021367/0001628280-24-021367-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662579/000162828024021367/cccc-20240508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T10:44:10.440346+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9baad4af9756c5d5aaf3c1a472122ac9e59ae577","claim":"C4 Therapeutics, Inc. reported first quarter ended March 31, 2024 results: revenue $3.0 million.","evidence_excerpt":"Total revenue for the first quarter of 2024 was $3.0 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1662579/000162828024021367/0001628280-24-021367-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$3.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}